A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

Overview of attention for article published in Investigational New Drugs, August 2012

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

patent: 54 patents

Readers on

mendeley: 75 Mendeley

So far, Altmetric has seen 54 patents that reference this research output.

Radiolabeled anti-LAG3 antibodies for immuno-PET imaging

Grant US-12721914-B2

United States of America

01 Sep 2026

Combined preparations for the treatment of cancer or infection

Grant US-12673088-B2

United States of America

07 Jul 2026

Bioengineered scaffolds for modulation of immune system and the uses thereof

Grant US-12661433-B2

United States of America

23 Jun 2026

LAG-3 antagonist therapy for lung cancer

Grant US-12565528-B2

United States of America

03 Mar 2026

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 50 additional patents.